IP Library › Granted Patent US 12,109,218
Granted Patent B2
US 12,109,218 · App. 17/548,755 · Granted Oct 8, 2024

Compositions of grapiprant and methods for using the same

Inventors: Lesley Rausch-Derra (Parkville, MO); Tamara Newbold (Martinsville, NJ); Gopinath Devaraj (Auckland, NZ); Akemi Shiraishi (Auckland, NZ)
Assignee: ARATANA THERAPEUTICS, INC.
A61K31/64A61K9/0053A61K9/2009A61K9/2013A61K9/2018A61K9/2027A61K9/2054A61K9/2059A61K31/437
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,218
App. No.
17/548,755
Granted
Oct 8, 2024
Kind
B2
Abstract

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

Claims (16)

1. A method for treating pain and inflammation in a cat or a dog, the method comprising administering to the cat or the dog an oral pharmaceutical composition comprising a therapeutically effective amount of grapiprant and one or more excipients;

wherein the therapeutically effective amount of grapiprant is administered at a dosage rate of 2 mg per kilogram bodyweight of the cat or the dog once per day; and

wherein the oral pharmaceutical composition is administered with or without food.

2. The method of claim 1 , wherein the administering achieves a C max of grapiprant of 375 ng/ml to 10000 ng/mL at a Tax of 0.4 to 3.4 hours.

3. The method of claim 2 , wherein the administering achieves a C max of grapiprant of 750 ng/mL to 4000 ng/mL.

4. The method of claim 3 wherein the administering achieves a C max of grapiprant of 1300 ng/mL to 4000 ng/mL.

5. The method of claim 2 , wherein the administering achieves the C max of grapiprant at a T max of 0.7 to 1.7 hours.

6. The method of claim 3 , wherein the administering achieves the C max of grapiprant at a T max of 0.5 to 1.0 hours.

7. The method of claim 1 , wherein the pharmaceutical composition further comprises 1% to 30% flavorant (w/w of the total composition).

8. The method of claim 7 , wherein the pharmaceutical composition comprises 5% to 15% flavorant (w/w of the total composition).

9. The method of claim 1 , wherein the pharmaceutical composition is administered for 6 days to 9 months.

10. The method of claim 9 , wherein the pharmaceutical composition is administered for 9 to 21 days.

11. The method of claim 10 , wherein the pharmaceutical composition is administered for 12 to 14 days.

12. The method of claim 1 , wherein the administering occurs from about 10 hours to about 18 hours before a surgery is performed on the cat or the dog.

13. The method of claim 1 , wherein the pharmaceutical composition comprises sodium lauryl sulfate.

14. The method of claim 1 , wherein the composition after administering causes no clinically significant adverse gastrointestinal event or changes in liver, kidney, and coagulation parameters in the cat or the dog.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2023
From: RAUSCH-DERRA, LESLEY; NEWBOLD, TAMARA; DEVARAJ, GOPINATH; SHIRAISHI, AKEMI
To: ARATANA THERAPEUTICS, INC.
Reel/Frame 063704/0127 →
Continuity (4)
Continuation 15144609 · May 2, 2016
Division 14639898 · Mar 5, 2015
Provisional Application 62089713 · Dec 9, 2014
Related Publication 20220096501A1 · Mar 31, 2022
Cited By (1)
US 12,478,633